首页> 外文期刊>Annals of surgical oncology >The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma.
【24h】

The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma.

机译:趋化因子受体CXCR4和CCR7与甲状腺乳头状癌的肿瘤大小和侵袭性的病理学指标有关。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Functional chemokine receptors are expressed in many malignant tumors, including papillary thyroid carcinoma (PTC). These receptors promote tumor growth and metastasis in response to endogenous chemokines. The purpose of this study was to examine the expression of two chemokine receptors-CXCR4 and CCR7-in a series of PTCs. We hypothesized that CXCR4 and CCR7 would correlate with indicators of tumor aggressiveness, including tumor size, extrathyroidal extension (ETE), angiolymphatic invasion (ALI), and lymph node metastasis. METHODS: CXCR4 and CCR7, as well as their specific chemokine ligands (CXCL12 and CCL21, respectively), were assessed in 88 PTCs from 65 patients using a semiquantitative measure of immunohistochemical (IHC) staining intensity for each molecule. Staining intensity was compared with clinicopathologic features including patient age, gender, tumor size, multifocality, ETE, ALI, and lymph node metastasis. Differences in CXCR4 and CCR7 mRNA levels were sought in a subset of tumors using gene microarrays and quantitative RT-PCR. [Statistics: t test, Mann-Whitney U test; P < .05]. RESULTS: High-intensity IHC staining for CXCR4 was associated with larger tumor size (P = .02), while PTCs exhibiting ETE, ALI, or lymph node metastasis showed higher-intensity IHC staining for CCR7 than those without (P = .01, .03, and .01, respectively). CCR7 mRNA levels were also higher in tumors with ALI (P = .04). CONCLUSION: Expression of CXCR4 and CCR7 by PTCs is associated with indicators of tumor aggressiveness, including tumor size, ETE, ALI, and lymph node metastasis. Further studies are necessary to define the mechanisms underlying this association and to determine its potential prognostic and therapeutic implications.
机译:背景:趋化因子受体在许多恶性肿瘤中表达,包括甲状腺乳头状癌(PTC)。这些受体响应内源性趋化因子而促进肿瘤生长和转移。这项研究的目的是检查两种趋化因子受体CXCR4和CCR7在一系列PTC中的表达。我们假设CXCR4和CCR7与肿瘤侵袭性指标相关,包括肿瘤大小,甲状腺外扩展(ETE),血管淋巴管浸润(ALI)和淋巴结转移。方法:采用半定量方法对每个分子的免疫组化(IHC)染色强度,对来自65位患者的88个PTC进行了CXCR4和CCR7及其特异性趋化因子配体(分别为CXCL12和CCL21)的评估。将染色强度与临床病理特征(包括患者年龄,性别,肿瘤大小,多灶性,ETE,ALI和淋巴结转移)进行比较。使用基因芯片和定量RT-PCR,在一部分肿瘤中寻找CXCR4和CCR7 mRNA水平的差异。 [统计:t检验,Mann-Whitney U检验; P <.05]。结果:CXCR4的高强度IHC染色与更大的肿瘤大小相关(P = .02),而表现出ETE,ALI或淋巴结转移的PTCs的CCR7的高强度IHC染色比无CXCR4的(P = .01, .03和.01)。患有ALI的肿瘤中CCR7 mRNA水平也更高(P = .04)。结论:PTCs表达CXCR4和CCR7与肿瘤侵袭性指标有关,包括肿瘤大小,ETE,ALI和淋巴结转移。有必要进行进一步的研究以确定这种关联的机制,并确定其潜在的预后和治疗意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号